Allogene Therapeutics ALLO Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's total liabilities?
- Allogene Therapeutics (ALLO) reported total liabilities of $117.08M in Q1 2026.
- How has Allogene Therapeutics's total liabilities changed year-over-year?
- Allogene Therapeutics's total liabilities decreased by 4.5% year-over-year, from $122.59M to $117.08M.
- What is the long-term trend for Allogene Therapeutics's total liabilities?
- Over 5 years (2020 to 2025), Allogene Therapeutics's total liabilities has grown at a -3.6% compound annual growth rate (CAGR), from $148.21M to $123.36M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.